Groundbreaking stem cell trial for knee osteoarthritis
The Department of Health - Abu Dhabi (DoH), has successfully completed a groundbreaking clinical trial in Abu Dhabi, in collaboration with Cellcolabs and Burjeel Holdings.
Developed by Swedish biotech company Cellcolabs, StromaForte has shown a favourable safety profile and significant therapeutic potential for knee osteoarthritis, marking a significant step in evaluating cell-based therapies for degenerative joint diseases.
The study evaluated the regenerative properties of Mesenchymal Stem Cells (MSCs), a type of stem cell known for its ability to reduce inflammation and repair and regenerate damaged tissues. Found naturally in the body, MSCs function as biological mediators by detecting areas of stress or injury and signalling the body to initiate its own healing process, rather than simply replacing damaged cells.
In this clinical trial, patients received MSC injections derived from carefully screened healthy donors aged 18-30, directly into their affected knee joints. The goal was to confirm safety, ease pain, reduce inflammation and potentially repair cartilage damage, offering a potential alternative to surgery for those suffering from knee osteoarthritis.
The clinical trial was led by Dr. Oussama Chaar, consultant Orthopaedic Surgeon and Dr. Veerabahu Muthusamy, specialist Orthopaedic Surgeon, and conducted at Burjeel Medical City and Burjeel Hospital from November 2023 to October 2024, where patients received a single dose of 50 million MSCs via ultrasound-guided injections.
The results of the first phase (Phase I/II) of the trial have been encouraging, meeting its primary endpoint of safety confirmed by an independent safety monitoring board.
Patients reported a significant reduction in pain levels, as measured by the Visual Analogue Scale (VAS), and an overall improvement in their quality of life, enabling them to move more comfortably and engage in daily activities with greater ease. Importantly, the treatment was well tolerated, with no serious adverse events reported.
To further evaluate the therapy's efficacy, provide deeper insights into the therapy's impact, MRI scans have been conducted with detailed findings set to be presented at Abu Dhabi Global Health Week in April 2025.
Dr. Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health - Abu Dhabi, highlighted, 'The successful completion of this clinical trial is a testament to Abu Dhabi's robust regulatory oversight and its growing appeal as a hub for cutting-edge medical research.
WAM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Etihad
9 hours ago
- Al Etihad
Khalifa University climbs 25 places to rank 177th globally in QS World University Rankings 2026
22 June 2025 13:12 ABU DHABI (ALETIHAD)Khalifa University of Science and Technology has climbed 25 places to be ranked 177th globally in the QS World University Rankings 2026, securing a spot among the world's top 200 eight consecutive years, Khalifa University has remained the top institution in the UAE, reinforcing its status as a national leader in higher education and the 2026 edition, the university leads across several key indicators including 11th in the world for International Faculty, top in UAE for International Students, Citations per Faculty, and Faculty Student Ratio and 37th globally for Academic Reputation, affirming its leadership in attracting global talent and producing high-impact scientific new QS rankings evaluated more than 8,467 universities from across 106 countries, with Khalifa University leading all 12 universities from the UAE, with a Graduate Employment Rate of an impressive 94 per Ebrahim Al Hajri, President, Khalifa University, said: 'As global academic and research landscape evolve, our consistent climb to reach the top 200 in the 2026 QS World University Rankings reinforces Khalifa University's status as a driving force in science and technology, particularly among researchers and students seeking world-class opportunities closer to home. "The 177th rank remains a testament to our faculty and students whose work continues to make a positive impact, while highlighting our global growing presence. Through our diverse academic community and our expanding international and regional industry collaborations, we are consistently contributing to meeting UAE's ambitions in knowledge economy leadership.' Source: Aletihad - Abu Dhabi
The National
a day ago
- The National
UAE evacuates critically injured child from Gaza for hospital treatment
A three-year-old boy seriously injured in an air strike on Gaza is on the road to recovery after receiving urgent treatment in the UAE. Hatim Awad suffered major injuries, including second and third-degree burns to his body, in an Israeli attack on the enclave. The strike killed his entire family. Hatim was evacuated under the UAE's Operation Chivalrous Knight 3 initiative, a humanitarian mission launched last year under the directive of President Sheikh Mohamed. The child arrived at Sheikh Shakhbout Medical City in Abu Dhabi on June 12 to begin comprehensive treatment, Dr Abdulqader Almessabi, chief medical officer at the hospital, said in a report by state news agency Wam. Dr Almessabi added that Hatim's condition has since improved significantly. His evacuation was co-ordinated with other authorities to ensure his safety throughout the journey to the hospital.
TECHx
a day ago
- TECHx
Abu Dhabi, Abbott Partner to Boost Local Pharma Sector
Home » Smart Sectors » Healthcare » Abu Dhabi, Abbott Partner to Boost Local Pharma Sector The Department of Health, Abu Dhabi (DoH), the healthcare sector regulator in Abu Dhabi, announced a strategic partnership with global healthcare leader Abbott. The agreement was signed during the BIO International Convention held in Boston, USA. The partnership aims to localise pharmaceutical manufacturing in Abu Dhabi. It also focuses on advancing digital health solutions across the emirate. Officials revealed that the collaboration builds on Abu Dhabi's advanced life sciences infrastructure. This move supports the emirate's goal to reduce dependency on imports and strengthen supply chain resilience. It further reflects Abu Dhabi's commitment to fostering a self-sufficient and sustainable healthcare ecosystem. Dr. Noura Al Ghaithi, Undersecretary of DoH, stated that the partnership follows the recent launch of the Health, Endurance, Longevity and Medicine (HELM) Cluster in Abu Dhabi. She added that the emirate is equipped with an integrated infrastructure to support local manufacturing and R&D. She said the agreement would position Abu Dhabi as a regional healthcare hub and leader in life sciences. According to her, aligning DoH's strategic vision with Abbott's global expertise will accelerate the delivery of innovative healthcare products and solutions. The collaboration is built around four key pillars: Localising Abbott's pharmaceutical portfolio and developing biosimilars. Advancing digital transformation through electronic patient information leaflets. Launching education programs to strengthen the healthcare workforce. Supporting regulatory alignment and joint R&D initiatives. Mazen Bachir, Regional Director for Abbott's established pharmaceuticals business in the Gulf, Emerging Markets and Levant, reported that this partnership will enhance healthcare resilience and innovation in Abu Dhabi. He highlighted Abbott's ongoing commitment to the UAE's healthcare system. He noted that the partnership will also include digitising life sciences product information and launching training initiatives to build local capabilities. In addition, both parties will explore opportunities for joint research and development. DoH also reported that a high-level delegation has embarked on a strategic mission to the United States from 15 to 21 June 2025. The delegation will conduct over 20 meetings with public and private sector leaders. These meetings aim to promote knowledge exchange, attract investments, and sign new agreements that accelerate advanced health solutions. Representing Abu Dhabi's innovation ecosystem, the delegation includes: Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, and PureHealth. Etihad Cargo, New York University Abu Dhabi, Khalifa University, startAD, and Mohamed bin Zayed University of Artificial Intelligence (MBZUAI). This announcement highlights Abu Dhabi's global ambitions in life sciences and healthcare innovation.
